Next Article in Journal
TAM Receptors in the Pathophysiology of Liver Disease
Previous Article in Journal
Biliary hCGβ Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients
Review

Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B

1
Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Ehime 791-0295, Japan
2
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka 1000, Bangladesh
*
Author to whom correspondence should be addressed.
Academic Editor: Giuseppe Colucci
Livers 2022, 2(1), 1-14; https://doi.org/10.3390/livers2010001
Received: 26 October 2021 / Revised: 16 December 2021 / Accepted: 27 December 2021 / Published: 6 January 2022
Millions of people of the world suffer from chronic hepatitis B (CHB), a pathological entity in which the patients are chronically infected with hepatitis B virus (HBV) and express hepatitis B surface antigen (HBsAg) and HBV DNA, as well as evidence of liver damages. Considerable numbers of CHB patients develop cirrhosis of the liver and hepatocellular carcinoma if untreated. Two groups of drugs (interferons and nucleoside analogs) are used to treat CHB patients, but both are endowed with considerable adverse effects, increased costs, extended duration of therapy, and limited efficacy. Thus, there is a pressing need to develop new and innovative therapeutics for CHB patients, and many such drugs have been developed during the last four decades. Some of these drugs have inspired considerable optimism to be a game-changer for the treatment of CHB. Here, we first discuss why ongoing therapeutics such as interferon and nucleoside analogs could not stand the test of time. Next, we dissect the scope and limitation of evolving therapies for CHB by dissecting the cellular and molecular mechanisms of some of these innovative therapeutics. View Full-Text
Keywords: chronic hepatitis B; antiviral drugs; innovative drugs; mechanism of action chronic hepatitis B; antiviral drugs; innovative drugs; mechanism of action
Show Figures

Figure 1

MDPI and ACS Style

Akbar, S.M.F.; Al Mahtab, M.; Yoshida, O.; Hiasa, Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022, 2, 1-14. https://doi.org/10.3390/livers2010001

AMA Style

Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers. 2022; 2(1):1-14. https://doi.org/10.3390/livers2010001

Chicago/Turabian Style

Akbar, Sheikh M.F., Mamun Al Mahtab, Osamu Yoshida, and Yoichi Hiasa. 2022. "Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B" Livers 2, no. 1: 1-14. https://doi.org/10.3390/livers2010001

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop